THOMAS FRANK E 4

What Happened

• Thomas Frank, a director of Larimar Therapeutics, acquired 5,000 shares of Larimar common stock on February 27, 2026. The shares were purchased at $5.00 each, for a total transaction value of $25,000. This was a purchase (transaction code P), which is a direct buy of common stock rather than a derivative or exercise.

Key Details

• Transaction date and price: Feb 27, 2026 — 5,000 shares at $5.00 per share.
• Total value: $25,000.
• Filing date: Form 4 filed March 2, 2026 (appears timely based on standard Form 4 rules).
• Shares owned after transaction: not disclosed in the filing.
• Footnote: The purchase “represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026.” (Footnote F1)

Context

• The shares were acquired through the company’s underwritten offering (per the footnote), meaning the insider participated in a planned offering rather than making an open-market speculative buy. Purchases by insiders can be informative to investors, but this transaction was part of a company offering rather than a spontaneous open-market trade.